Progestogens and membrane-initiated effects on the proliferation of human breast cancer cells

References

• Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321–333
   PubMed Web of Science ®Google Scholar
• The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 2004;291:1701–12
   PubMed Web of Science ®Google Scholar
• Stefanick ML, Anderson GL, Margolis KL, . Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295:1647–57
   PubMed Web of Science ®Google Scholar
• Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107:103–11
   PubMed Web of Science ®Google Scholar
• Schoonen WGEJ, Joosten JWH, Kloosterboer HJ. Effects of two classes of progestins, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells. 1. MCF-7 cell lines. J Steroid Biochem Mol Biol 1995;55:423–37
   PubMed Web of Science ®Google Scholar
• Cappelletti V, Miodini P Fioravanti L, DiFronzo G. Effect of progestin treatment on estradiol- and growth factor-stimulated breast cancer cell lines. Anticancer Res 1995;15:2551–6
   PubMed Web of Science ®Google Scholar
• Krämer EA, Seeger H, Krämer B, Wallwiener D, Mueck AO. The effect of progesterone, testosterone and synthetic progestogens on growth factor- and estradiol-treated human cancerous and benign breast cells. Eur J Obstet Gynecol Reprod 2006;27: 139–41
   Google Scholar
• Catherino WH, Jeng MH, Jordan VC. Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism. Br J Cancer 1993;67:945–52
   PubMed Web of Science ®Google Scholar
• Franke HR, Vermes I. Differential effects of progestogens on breast cancer cell lines. Maturitas 2003;46(Suppl 1):S55–8
   PubMedGoogle Scholar
• Cahill MA. Progesterone receptor membrane component 1: an integrative review. J Steroid Biochem Mol Biol 2007;105:16–36
   PubMed Web of Science ®Google Scholar
• Meyer C, Schmid R, Scriba PC, Wehling M. Purification and partial sequencing of high-affinity progesterone-binding site(s) from porcine liver membranes. Eur J Biochem 1996;239:726–33
   PubMedGoogle Scholar
• Munton RP, Tweedie-Cullen R, Livingstone-Zatchej M, . Qualitative and quantitative analyses of protein phosphorylation in naive and stimulated mouse synaptosomal preparations. Mol Cell Proteomics 2007;6:283–93
   PubMed Web of Science ®Google Scholar
• Ahmed IS, Rohe HJ, Twist KE, Craven RJ. PGRMC1 (progesterone receptor membrane component 1) associates with EGFR and regulates erlotinib sensitivity. Biol Chem 2010;285:24775–82
   Web of Science ®Google Scholar
• Neubauer H, Clare SE, Wozny W, . Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1. Breast Cancer Res 2008, 10: R85
   PubMed Web of Science ®Google Scholar
• Neubauer H, Chen R, Schneck H, . New insight on a possible mechanism of progestogens in terms of breast cancer risk. Horm Mol Biol Clin Invest 2011;6:185–92
   PubMedGoogle Scholar
• Mueck AO, Seeger H. The role of progestogens in breast cancer: experimental vs. clinical data. Menopausal Med 2006;14:1–6
   Google Scholar
• Seeger H, Mueck AO. HRT and breast cancer caused by progestogens? Experimental vs. clinical data. J Steroid Biochem Molecular Biol 2008;109:11–15
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Update 2006;12:169–78
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R. Pharmacological profile of progestins. Maturitas 2004;47:277–83
   PubMed Web of Science ®Google Scholar
• Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric 2005;8(Suppl 1): 3–63
   PubMed Web of Science ®Google Scholar
• Neubauer H, Adam G, Seeger H, . Membrane-initiated effects of progesterone on proliferation and activation of VEGF in breast cancer cells. Climacteric 2009;3:230–9
   Web of Science ®Google Scholar
• Jeng MH, Parker CJ, Jordan VC. Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation. Cancer Res 1992;52:6539–56
   PubMed Web of Science ®Google Scholar
• Seeger H, Wallwiener D, Mueck AO. The effect of progesterone and synthetic progestins on serum- and estradiol-stimulated proliferation of human breast cancer cells. Horm Metab Res 2003; 35:76–80
   PubMed Web of Science ®Google Scholar
• Mueck AO, Seeger H, Wallwiener D. Comparison of the proliferative effects of estradiol and conjugated equine estrogens on human breast cancer cells and impact of continuous combined progestogen addition. Climacteric 2004;6:221–7
   Web of Science ®Google Scholar
• Ebeling K, Ray R, Nischan P, Thomas DB. Kunde D, Stalsberg H. Combined oral contraceptives containing chlormadinone acetate and breast cancer: results of a case-control study. Br J Cancer 1991;63:804–8
   PubMed Web of Science ®Google Scholar
• Nischan P, Ebeling K. Oral contraceptives containing chlormadinone acetate and cancer incidence at selected sites in the German Democratic Republic – a correlation analysis. Int J Cancer 1984; 34:671–4
   PubMed Web of Science ®Google Scholar
• Persson I, Yuan J, Bergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy – long-term follow-up of a Swedish cohort. Int J Cancer 1996;67:327–32
   PubMed Web of Science ®Google Scholar
• Catherino WH, Jordan VC. Nomegestrol acetate, a clinically useful 19-norprogesterone derivative which lacks estrogenic activity. J Steroid Biochem Mol Biol 1995;55:239–46
   PubMed Web of Science ®Google Scholar
• Botella J, Duranti E, Duc I, Cognet AM, Delansorne R, Paris J. Inhibition by nomegestrol acetate and other synthetic progestins on proliferation and progesterone receptor content of T47-D human breast cancer cells. J Steroid Biochem Mol Biol 1994; 50:41–7
   PubMed Web of Science ®Google Scholar
• Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol 2009;113:65–73
   PubMed Web of Science ®Google Scholar
• Chu MC, Zhang X, Gentzschein E, Stanczyk FZ, Lobo RA. Formation of ethinyl estradiol in women during treatment with norethindrone acetate. J Clin Endocrinol Metab 2007;92:2205–7
   PubMed Web of Science ®Google Scholar